@article{b906deae8c634ff1a38a52d2028878b6,
title = "Structure-based classification of EGFR mutations informs inhibitor selection for lung cancer therapy",
abstract = "EGFR oncogenic mutations predict sensitivity to EGFR inhibitors in NSCLC, but less is known about EGFR “variants of unknown significance.” Using preclinical models, 3D structure analyses, and patient response data, Robichaux et al. show in Nature that mutations in structural regions of EGFR predict responses to different EGFR inhibitors.",
author = "Paul Yenerall and Ralf Kittler and John Minna",
note = "Funding Information: This article was supported by funding from the Simmons Comprehensive Cancer Center at UT Southwestern (developmental funds to R.K. from P30CA142543 ), CPRIT ( RP120732-P3 to R.K., RP160652 to J.D.M.), the National Institutes of Health (NCI SPORE in lung cancer, CA07090,7 to J.D.M. and R01CA200787 to R.K.), and the Margot Johnson Foundation to J.D.M. R.K. is a John L. Roach Scholar in Biomedical Research and a CPRIT Scholar in Cancer Research. Publisher Copyright: {\textcopyright} 2021 Elsevier Inc.",
year = "2021",
month = nov,
day = "8",
doi = "10.1016/j.ccell.2021.10.012",
language = "English (US)",
volume = "39",
pages = "1455--1457",
journal = "Cancer Cell",
issn = "1535-6108",
publisher = "Cell Press",
number = "11",
}